CDC

HPV vaccination leads to significant decline in cervical precancers

March 4, 2025

A recent CDC report highlights the substantial impact of the HPV vaccine on reducing cervical precancers in the U.S. The Human Papillomavirus Vaccine Impact Monitoring Project (HPV-IMPACT) tracked cervical precancer incidence from 2008 to 2022 across 5 sites. The study found a 79% decrease in cervical intraepithelial neoplasia grade 2 or higher (CIN2+) and an 80% decrease in higher-grade precancers (CIN3+) among women aged 20 to 24, the age group most likely to have been vaccinated. Additionally, CIN3+ rates among women aged 25 to 29 decreased by 37%. The data are consistent with considerable impact of HPV vaccination for preventing cervical precancers among women in the age groups most likely to have been vaccinated and support existing recommendations to vaccinate children at the routinely recommended ages as a cancer prevention measure.

Source:

Gargano, J., et al. (2025, February 27). CDC. Trends in Cervical Precancers Identified Through Population-Based Surveillance — Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008–2022. https://www.cdc.gov/mmwr/volumes/74/wr/mm7406a4.htm